Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Yoshikazu Yahata"'
Autor:
Katsumi Mizuta, Makoto Kuroda, Masayuki Kurimura, Yoshikazu Yahata, Tsuyoshi Sekizuka, Yoko Aoki, Tatsuya Ikeda, Chieko Abiko, Masahiro Noda, Hirokazu Kimura, Tetsuya Mizutani, Takeo Kato, Toru Kawanami, Tadayuki Ahiko
Publikováno v:
Emerging Infectious Diseases, Vol 18, Iss 11, Pp 1787-1793 (2012)
Human parechovirus has rarely been shown to cause clinical disease in adults. During June–August 2008, a total of 22 adults sought treatment at Yonezawa City Hospital in Yamagata, Japan, for muscle pain and weakness of all limbs; most also had feve
Externí odkaz:
https://doaj.org/article/07e22cb3e02640ef951c22a2be677012
Publikováno v:
Langmuir. 35:14566-14575
The development of quasi-solid electrolytes for electrical devices operating at high voltages is important for addressing future energy storage requirements. Here, we report a new method to fabricate quasi-solid electrolytes through the thermally ind
Autor:
Christopher B. Murray, Amalie L. Frischknecht, Jason Koski, Kohji Ohno, Jamie Ford, Nadia M. Krook, Robert A. Riggleman, Russell J. Composto, Yoshikazu Yahata
Publikováno v:
Macromolecules. 52:5110-5121
There are limited theoretically predicted phase diagrams for polymer nanocomposites (PNCs) because conventional modeling techniques are largely unable to predict the macroscale phase behavior of PN...
Publikováno v:
Nihon Naika Gakkai Zasshi. 106:807-812
Autor:
Yoshinobu Tsujii, Keiji Kimura, Shoko Marukane, Takaya Sato, Yohei Nakanishi, Kohji Ohno, Yoshikazu Yahata
Publikováno v:
Langmuir : the ACS journal of surfaces and colloids. 35(10)
Immiscible composite materials with controlled phase-separated structures are important in areas ranging from catalysis to battery. We succeeded in controlling the phase-separated structures of immiscible blends of polystyrene (PS) and two ionic liqu
Publikováno v:
Chemistry (Weinheim an der Bergstrasse, Germany). 25(8)
Monodisperse silica particles (SiPs) were surface-modified with a newly designed silane coupling agent comprising a triethoxysilane and an alkyl halide, namely, 6-(triethoxysilyl)hexyl 2-bromopropionate, which was further treated with potassium O-eth
Autor:
Kouji Nakanishi, Shota Konishi, Shigeru Yamago, Eiichi Kayahara, Atsushi Goto, Yoshinobu Tsujii, Yoshikazu Yahata, Akihiro Nomura
Publikováno v:
Macromolecules. 46:6777-6785
An organotellurium chain transfer agent (CTA) bearing a triethoxysilyl group at one end and a 2-methyltellanyl-2-methylpropionate group at the other was prepared and immobilized on the surface of a silicon wafer and silica nanoparticle (SiP). Surface
Autor:
Thomas Maschmeyer, Ying Ma, John Moraes, Sébastien Perrier, Chizuru Mori, Kohji Ohno, Yun Huang, Yoshinobu Tsujii, Yoshikazu Yahata
Publikováno v:
Macromolecules. 44:8944-8953
Monodisperse silica particles (SiPs) were surface-modified with a newly designed reversible addition–fragmentation chain transfer (RAFT) agent having a triethoxysilane moiety, 6-(triethoxysilyl) 2-(((methylthio)carbonothioyl)thio)-2-phenylacetate (
Autor:
Tetsuya Mizutani, Yoshikazu Yahata, Takeo Kato, Tatsuya Ikeda, Tadayuki Ahiko, Katsumi Mizuta, Makoto Kuroda, Chieko Abiko, Masahiro Noda, Masayuki Kurimura, Hirokazu Kimura, Toru Kawanami, Tsuyoshi Sekizuka, Yoko Aoki
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 18, Iss 11, Pp 1787-1793 (2012)
Emerging Infectious Diseases, Vol 18, Iss 11, Pp 1787-1793 (2012)
This virus typically causes illness in young children but was found to be associated with illness in adults.
Human parechovirus has rarely been shown to cause clinical disease in adults. During June–August 2008, a total of 22 adults sought tre
Human parechovirus has rarely been shown to cause clinical disease in adults. During June–August 2008, a total of 22 adults sought tre
Autor:
Takayoshi Toyota, Ryuichi Sano, Keiji Takenaka, Yoshikazu Yahata, Tsuneyoshi Saito, Akihisa Fujino, Akinori Ogyu
Publikováno v:
The Tohoku Journal of Experimental Medicine. 169:299-307
The effect of niceritrol at an ordinary dose (1500 mg/day) on the serum lipoprotein(a) (Lp(a)) concentration was investigated in 25 normolipidemic patients with coronary artery disease. The serum Lp(a) level was reduced by approximately 21% after 3 m